Cognitive Change Clinical Trial
Official title:
Investigating the Acute and Chronic Effects of an American Ginseng Root Extract on Cognition and Mood.
Ginseng refers to the extract of any slow growing perennial plant with a fleshy root,
deriving from the Panax genus of the Araliaceae family. Ginseng root has been used as an
intervention for the treatment of diabetes (Sotaniemi, Haapakoski & Rautio, 1995), boosting
cognitive function (Scholey et al., 2010) and improving mental health (Ellis & Reddy, 2002).
The most commonly used ginseng is Panax ginseng (Asia) and Panax quinquefolius (America).
Ginsensosides are considered the core phytochemical compounds that contribute to the alleged
beneficial effects of ginseng. In particular, ginsenosides Rb1 and Rg1 have been isolated and
investigated for effects on cognitive function (Shin et al., 2016).
Scholey et al. (2010) was one of the first studies to provide support for a beneficial
cognitive effect from American ginseng (Cereboostâ„¢), with better performance on working
memory in healthy young adults. Improvements were most profound for a single dose of 200 mg
on working memory tasks, specifically immediate word recall and numeric working memory speed.
Cereboost also increased self-rated calmness compared to placebo, suggesting ginseng can
enhance aspects of mood. Similarly, Ossoukhova et al. (2015) compared a single 200mg dose to
placebo to investigate whether beneficial cognitive effects extend to a middle-aged cohort.
Here, Cereboost significantly improved performance on the Cognitive Drug Research (CDR)
working memory factor, specifically improving spatial working memory at three hours post
dose.
Further study is required to evaluate ginseng specific effects with a standardized extract of
P. quinquefolius, such as Cereboostâ„¢ on healthy participants. Significant results will have
implications for investigating the neurocognitive effects in other populations, such as those
with cognitive and memory problems.
The study comprises of a familiarisation visit and then two test days. The test days are
separated by a 2 week interval during which time participants will be asked to consume a
daily capsule for 14 days which will contain either an American ginseng root extract (200 mg
Cereboost and Maltodextrin) or an identical placebo that does not contain any of the active
ingredient. Participants will be asked to restrict their intake of certain foods for 48 hours
before test days and intake of alcohol and caffeinated drinks for 24 hours prior. All
participants will be required to fast overnight prior to each of the study days. Participants
may withdraw at any time without giving any reason. In addition, a participant will be
withdrawn from the study if they request discontinuation, exhibit a serious adverse event to
any component of the test product, the participant significantly violates the exclusion or
inclusion criteria, an illness emerges and/or opinion is that withdrawal is appropriate.
An outline of each session is as follows:
1. Familiarisation/practice visit: Volunteers will attend the Nutritional Psychology unit
at the University of Reading, where they will receive a detailed explanation on the
study and will be asked to sign the informed consent form. Once consent has been given
the inclusion/exclusion criteria will be checked and measures of age, height and weight
will be taken. Participants will then be asked to fill out a food frequency
questionnaire before completing training on the cognitive test battery. Participants
will be given two food diaries, with each diary completed in the 48 hours before each
test day to check habitual diet and ensure they followed low flavonoid protocol. Finally
the PANAS - X will be administered to gain a measure of trait mood
2. Test visits: On arrival of their first test day, participants will be randomly assigned
to treatment (200 mg Cereboostâ„¢) or placebo condition. Each study day will begin at 9am
with breakfast before completion of the computerized test battery to establish baseline
performance. Participants will then take their allocated intervention and will be tested
on the cognitive and mood battery at 2, 4 and 6 hours after consumption. A standard
light lunch will be provided between the 2hr and 4 hr test points. On test visit 2,
participants will have completed a 14 day course of their intervention and will be
tested at the same time points at test visit 1, again receiving the intervention
directly after the baseline test battery. Finally the PANAS - X will be administered
again to gain a measure of trait mood following the 2 week intervention.
The computerized cognitive battery will include tests which are known to be sensitive to
nutritional manipulations (Lamport, 2012) and will last no more than 45 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05712005 -
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
|
||
Completed |
NCT05343208 -
Effectiveness of Online Therapy to Prevent Burnout
|
N/A | |
Active, not recruiting |
NCT05143294 -
Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
Completed |
NCT05267730 -
Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
Completed |
NCT03987477 -
Online Intervention to Modify Interpretation Biases in Depression
|
N/A | |
Completed |
NCT03695003 -
Cognitive Effects of Sage in Healthy Humans
|
N/A | |
Completed |
NCT05075850 -
Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
|
||
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03689348 -
Acute and Chronic Effects of Avena Sativa on Cognition and Stress
|
N/A | |
Active, not recruiting |
NCT05229705 -
Exercise in Older Adults at Risk for Type 2 Diabetes
|
N/A | |
Suspended |
NCT05001789 -
Cognitive Functioning in Opioid Use Disorder
|
N/A | |
Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT05543811 -
The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology
|
N/A | |
Recruiting |
NCT05699226 -
Amplitude Titration to Improve ECT Clinical Outcomes
|
N/A | |
Recruiting |
NCT05026541 -
Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators
|
N/A | |
Active, not recruiting |
NCT03255499 -
Efficacy of the MovinCog Intervention in Children
|
N/A | |
Not yet recruiting |
NCT06252376 -
Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD
|
N/A |